Ospemifene for Vaginal Dryness: What the Placebo Trial Found

An oral medicine can appeal when applying a vaginal treatment is difficult. Before discussing ospemifene, ask two separate questions: how much additional symptom relief did it provide, and does your health history permit its use?

Who was studied

The 2019 trial randomized 631 postmenopausal women aged 40–80 whose most bothersome symptom was moderate or severe vaginal dryness. Eligibility also required vaginal pH above 5 and no more than 5% superficial cells.¹

Ospemifene 60 mg daily with food was compared with placebo for 12 weeks; both groups could use supplied lubricant during sex.¹

At an appointment, describe whether discomfort is inside the vagina, on the outer skin, during penetration or present throughout the day. Give the start date and any product changes. Ask which findings support the proposed diagnosis before discussing a prescription.

How much dryness improved

On the 0–3 dryness scale, mean improvement was 1.29 points with ospemifene versus 0.91 with placebo: 0.38 points of additional improvement. The intention-to-treat groups contained 313 and 314 women; about 89% completed treatment.¹

Cell measurements and pH improved separately. There was no vaginal-estrogen comparator.¹ This comparison cannot rank the two prescriptions.

An earlier trial’s 314-woman dryness group did not show a statistically significant symptom difference in its intention-to-treat analysis, P=.080, despite improved cells and pH. Its per-protocol result was significant.² Reading only the favorable analysis would omit a pertinent result.

What twelve weeks cannot settle

Shionogi and Duchesnay funded the study; company employees coauthored it. Twelve weeks cannot establish long-term safety.¹

Current US prescribing information carries a boxed warning addressing endometrial cancer and cardiovascular disorders. Contraindications include unexplained genital bleeding, estrogen-dependent cancer, and current or past blood clots, stroke or heart attack. Unusual postmenopausal bleeding needs assessment.³

Bring your medication list and relevant diagnoses to the prescriber. Our ospemifene prescribing guide covers additional restrictions and interactions. Ask how your clinician will review symptoms, adverse effects and the need to continue treatment.

When an oral option fits the discussion

UK NICE⁴ guidance considers oral ospemifene when locally applied treatments are impractical, for example because of a disability.⁴ That recommendation addresses a particular treatment-selection problem; the US label and your local prescribing guidance still need checking.

Explain what makes local application difficult and what you have already tried. Ask what improvement would justify continuing an oral prescription and when you should report problems between visits. Agree on a review date before leaving.

Down There, Decoded includes “What to Say When You’re Embarrassed,” with ways to describe where a symptom occurs, what changed and when it started. Use that section to prepare the details you want heard. See the book.